Export 6 results:
Author Title [ Type(Asc)] Year
Filters: Author is Singh, Rajbir  [Clear All Filters]
Journal Article
Singh R, Hegde B, Von Baby B, Sadeep C, Kotla N, Chandrasekar B, Marepally S, Bodduluri H, Vemula PK, Jala VR.  2017.  Targeted delivery of microbial metabolite, urolithin A protects from chemically (DSS or TNBS) induced colitis in pre-clinical models. The Journal of Immunology. 198:65.6–65.6.
Singh R, Chandrashekharappa S, Vemula PKumar, Haribabu B, Jala VRao.  2020.  Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme.. Metabolites. 10(6) DOI:10.3390/metabo10060258.
Ghosh S, Singh R, Vanwinkle ZMatthew, Guo H, Vemula PKumar, Goel A, Haribabu B, Jala VRao.  2022.  Microbial metabolite restricts 5-fluorouracil-resistant colonic tumor progression by sensitizing drug transporters via regulation of FOXO3-FOXM1 axis.. Theranostics. 12(12):5574-5595. DOI:10.7150/thno.70754.
Kotla NG, Singh R, Baby BV, Rasala S, Rasool J, Hynes SO, Martin D, Egan LJ, Vemula PK, Jala VR, Rochev Y, Pandit A.  2022.  Inflammation-specific targeted carriers for local drug delivery to inflammatory bowel disease.. Biomaterials. 281:121364. DOI:10.1016/j.biomaterials.2022.121364.
Saha P, San Yeoh B, Singh R, Chandrasekar B, Vemula PKumar, Haribabu B, Vijay-Kumar M, Jala VR.  2016.  Gut Microbiota Conversion of Dietary Ellagic Acid into Bioactive Phytoceutical Urolithin A Inhibits Heme Peroxidases.. PLoS One. 11(6):e0156811. DOI:10.1371/journal.pone.0156811.
Singh R, Chandrashekharappa S, Bodduluri SR, Baby BV, Hegde B, Kotla NG, Hiwale AA, Saiyed T, Patel P, Vijay-Kumar M, Langille MGI, Douglas GM, Cheng X, Rouchka EC, Waigel SJ, Dryden GW, Alatassi H, Zhang H-G, Haribabu B, Vemula PK et al..  2019.  Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway.. Nat Commun. 10(1):89. DOI:10.1038/s41467-018-07859-7.